Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Fresenius Medical profit drops less than feared, labour shortages ease

Published 09/05/2023, 06:29
Updated 09/05/2023, 08:47
© Reuters. FILE PHOTO: Samples of products of Fresenius and Fresenius Medical Care are on display during the company's annual news conference at their head quarters in Bad Homburg Germany, February 20, 2019.  REUTERS/Kai Pfaffenbach/File Photo/File Photo

By Ludwig Burger

FRANKFURT (Reuters) -Fresenius Medical Care said on Tuesday labour shortages were slowly easing as the German dialysis specialist reported a drop in first-quarter adjusted operating income that was not as steep as some analysts had expected.

Adjusted operating income dropped to 354 million euros ($390 million), compared with the median analysts' estimate of 335 million posted on the company's website.

"The first quarter confirmed the trends towards improving treatment volumes and towards a stabilizing labor environment in the U.S," said CEO Helen Giza.

It confirmed its full-year outlook, saying adjusted operating income would likely remain flat or decline by up to a "high-single digit" percentage in 2023, which it has described as a transition year towards earnings growth recovery in 2024.

The dialysis group's parent, German healthcare group Fresenius SE (ETR:FREG) has said this year it would cede control over the struggling dialysis firm, but keep its stake for now as part of a turnaround plan.

Fresenius said on Tuesday it was on track with those plans.

The move has been viewed by some investors as a prelude to an eventual sale of its stake in the dialysis group.

Fresenius Medical, which was hit hard by a high rate of COVID-19 deaths among its patients, said this burden was easing, though excess mortality continued to weigh on growth.

Its parent Fresenius said on Tuesday first-quarter operating earnings slipped a currency-adjusted 10%, also a better-than-expected result.

Shares in Fresenius Medical gained 1.4% at the open, while parent Fresenius' stock rose 3% to a two-month high.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"This is a good start to the year with improving fundamental signs in the business," Barclays (LON:BARC) analysts said.

Fresenius parent group CEO Michael Sen, who took over the helm last October, is cutting costs and has said the group would focus on generic hospital drugs unit Kabi and hospitals operator Helios, while Fresenius Medical and hospital project development firm Vamed would be treated as financial investments.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.